glp-1 weight loss news

Weight loss drug is not taking easy way out

Massive study looks at benefits, risks of GLP-1 weight-loss drugs

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

New York Post on MSN · 1d

Oprah Winfrey reveals taking GLP-1 weight-loss drug made her realize what she got wrong about ‘thin people’

The media queen also confessed that she was reluctant to take a GLP-1 drug because she felt it was “the easy way out.” That changed after a special on weight loss with experts and clinicians that she taped in July 2023. The panel discussion left her with her “biggest aha moment” about the medication.

E! · 11h

Oprah Winfrey Shares What She Learned About “Thin People” After Experience With Weight-Loss Drug

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin people.”

4don MSN

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

16hon MSN

Novo Nordisk reports 22% weight loss in early subcutaneous amycretin trial

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Demand for loose skin surgery rises with GLP-1 weight loss meds

As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...

13h

Novo Nordisk next-gen shot shows 22% weight loss in early results

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

The Washington Post5d

Sweeping review suggests weight-loss drugs’ effect on 175 conditions

A study by the Department of Veterans Affairs on the relationship between GLP-1 weight-loss drugs and 175 diseases and conditions supports a lot of what scientists already suspected about ...

IFLScience4d

Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

15hon MSN

Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss

Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...

10h

Novo Nordisk stock pops on phase I data for new weight-loss drug amycretin

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Diabetes startup Virta Health is now prescribing Ozempic for weight loss in a push toward profitability and IPO

The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results